Please assess the completion status of the following clinical trial:

Trial Title: Effect of Long Acting Anticholinergic on Nocturnal Incontinence After Radical Cystectomy and Orthotopic Neobladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who passed at least one year follow up after the procedure.~* Patients who have no symptoms or signs of oncological failure (local recurrence or distant metastasis).~* Presence of NI with normal daytime continence assessed by the Arabic version of short form International Consultation on Incontinence questionnaire (ICIQ-UI Short Form).18~* Normal renal function (eGFR ˃50 ml/min /1.73m2) calculated by the Modification Of Diet in Renal Disease study equation.~* Ability to provide informed consent.~Exclusion Criteria:~* Patients who did not pass one year postoperative.~* Presence of oncological failure.~* Totally continent patient or who has daytime incontinence or chronic urine retention.~* Impaired renal function.~* Uncontrolled DM or hypertension.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tolterodine-treated group (Type: ACTIVE_COMPARATOR): they will receive long acting tolterodine 4 mg at bedtime for 4 weeks. After that re-evaluation. then stop medication for two weeks (washout period).
- placebo-control group (Type: PLACEBO_COMPARATOR): they will receive placebo at bedtime for 4 weeks. After that re-evaluation. then stop for two weeks (washout period). Then re-evaluate the nocturnal incontinence status and crosed over to receive long acting tolterodine 4 mg for 4 weeks. at the end the nocturnal incontinence status will be evaluated

Based on this trial design, predict the completion outcome and termination type (if applicable).